• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Ann Transl Med . Identification of novel drug targets for the risk and prognosis of COVID-19

tetano

Editor, Senior Moderator
Ann Transl Med


. 2022 Jun;10(11):624.
doi: 10.21037/atm-21-6612.
Identification of novel drug targets for the risk and prognosis of COVID-19


Yi-Han Gan[SUP] #[/SUP][SUP] 1 [/SUP], Ya-Nan Ou[SUP] #[/SUP][SUP] 2 [/SUP], Yu-Xiang Yang[SUP] 1 [/SUP], Yue-Ting Deng[SUP] 1 [/SUP], Yi Liu[SUP] 2 [/SUP], Lan Tan[SUP] 2 [/SUP], Jin-Tai Yu[SUP] 1 [/SUP]



Affiliations

Abstract

Background: Since the epidemic continues, there is a pressing need to improve our understanding of coronavirus disease 2019 (COVID-19). Mendelian randomization (MR) studies provide us with a method to explore the causality between circulating proteins and COVID-19 susceptibility and severity. We aim to find new perspectives on the pathological mechanism of the disease and possible drug targets for treatment based on this study.
Methods: We conducted a phenome-wide MR study to prioritize circulating proteins causally associated with COVID-19 susceptibility, which was defined as "patients tested positive for COVID-19 vs. population controls", and severity, which was defined as "patients hospitalized with COVID-19 vs. population controls". And we repeated the analysis for different definition of COVID-19 susceptibility, severity and control groups.
Results: Association of three circulating proteins with COVID-19 susceptibility and severity were demonstrated via our study. C-C motif chemokine 4 (OR =1.887, 95% CI: 1.608-2.165, P=8.04×10[SUP]-6[/SUP]) and 2'-5'-oligoadenylate synthase 1 (OR =0.511, 95% CI: 0.266-0.757, P=8.51×10[SUP]-8[/SUP]) were found respectively positively and negatively correlated with increased COVID-19 severity. Tissue factor, contrary to previous studies, was found associated with decreased COVID-19 susceptibility (OR =0.667, 95% CI: 0.484-0.850, P=1.47×10[SUP]-5[/SUP]) and decreased COVID-19 severity (OR =0.459, 95% CI: 0.132-0.786, P=3.01×10[SUP]-6[/SUP]).
Conclusions: Genetic evidence supports C-C motif chemokine 4 as a risk factor for COVID-19 severity, and 2'-5'-oligoadenylate synthase 1 as a protective factor for COVID-19 severity. The causal association between tissue factor and COVID-19 is contrary to the previous studies, needing further analyses. Further research is warranted to assess the viability of C-C motif chemokine 4 and 2'-5'-oligoadenylate synthase 1 as well as their downstream pathways as drug targets for anti-inflammatory and anti-virus treatment in severe cases.

Keywords: Mendelian randomization (MR); coronavirus disease 2019 (COVID-19); proteomics.
 
Back
Top Bottom